Type 2 diabetes: A risk factor for liver mortality and complications in hepatitis B cirrhosis patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 3, 2015, Pages 591-599

  Hsiang, John C ^a   Gane, Edward J ^b   Bai, Wayne W ^a   Gerred, Stephen J ^a  

^a MIDDLEMORE HOSPITAL   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Chronic hepatitis B; Cirrhosis; Cirrhosis complications; Hepatocellular carcinoma; Insulin; Liver related mortality; Sulphonylurea; Type 2 diabetes mellitus

Indexed keywords

ADEFOVIR; ENTECAVIR; HEMOGLOBIN A1C; INSULIN; LAMIVUDINE; METFORMIN; SULFONYLUREA; TELBIVUDINE; TENOFOVIR;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CANCER INCIDENCE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPLICATION; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; HEPATITIS B; HIGH RISK PATIENT; HUMAN; INSULIN TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; SURVIVAL RATE; INCIDENCE; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTOR; TIME;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HEPATITIS B; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MORBIDITY; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 84923241236     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12790     Document Type: Article

References (32)

1. Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 1997; 337: 1733-1745.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004; 11: 97-107.
3. Realdi G, Fattovich G, Hadziyannis S etal. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J. Hepatol. 1994; 21: 656-666.
4. Fattovich G, Pantalena M, Zagni I etal. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am. J. Gastroenterol. 2002; 97: 2886-2895.
5. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol. 2008; 48: 335-352.
6. Wong VW, Wong GL, Chu WC etal. Hepatitis B virus infection and fatty liver in the general population. J. Hepatol. 2012; 56: 533-540.
7. Hsu CS, Liu CH, Wang CC etal. Impact of hepatitis B virus infection on metabolic profiles and modifying factors. J. Viral Hepat. 2012; 19: e48-57.
8. Huo TI, Wu JC, Lee PC, Tsay SH, Chang FY, Lee SD. Diabetes mellitus as a risk factor of liver cirrhosis in patients with chronic hepatitis B virus infection. J. Clin. Gastroenterol. 2000; 30: 250-254.
9. Wong GL, Wong VW, Choi PC etal. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009; 58: 111-117.
10. Lee IC, Huang YH, Chan CC etal. Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. Clin. Nutr. 2011; 30: 647-652.
11. Wong GL, Chan HL, Yu Z etal. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B-a prospective cohort study with paired transient elastography examinations. Aliment. Pharmacol. Ther. 2014; 39: 883-893.
12. Huang YW, Wang TC, Lin SC etal. Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study. Clin. Infect. Dis. 2013; 57: 1695-1702.
13. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-2038.
14. Giovannucci E, Harlan DM, Archer MC etal. Diabetes and cancer: a consensus report. CA Cancer J. Clin. 2010; 60: 207-221.
15. Marcellin P, Ziol M, Bedossa P etal. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009; 29: 242-247.
16. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
17. Executive summary: standards of medical care in diabetes-2009. Diabetes Care 2009; 32 (Suppl. 1): S6-12.
18. Runyon BA, Committee APG. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-2107.
19. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
20. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Practice Guidelines Committee of the American Association for the Study of Liver D, Practice Parameters Committee of the American College of G. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 922-938.
21. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006; 43: 1295-1302.
22. Chen CL, Yang HI, Yang WS etal. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111-121.
23. Ko WH, Chiu SY, Yang KC, Chen HH. Diabetes, hepatitis virus infection and hepatocellular carcinoma: a case-control study in hepatitis endemic area. Hepatol. Res. 2012; 42: 774-781.
24. Huo TI, Wu JC, Lui WY etal. Diabetes mellitus is a recurrence-independent risk factor in patients with hepatitis B virus-related hepatocellular carcinoma undergoing resection. Eur. J. Gastroenterol. Hepatol. 2003; 15: 1203-1208.
25. Chao LT, Wu CF, Sung FY etal. Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. Carcinogenesis 2011; 32: 876-881.
26. Hassan MM, Curley SA, Li D etal. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010; 116: 1938-1946.
27. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 2010; 30: 750-758.
28. Ruiter R, Visser LE, van Herk-Sukel MP etal. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 2012; 35: 119-124.
29. Lucchesi AN, Freitas NT, Cassettari LL, Marques SF, Spadella CT. Diabetes mellitus triggers oxidative stress in the liver of alloxan-treated rats: a mechanism for diabetic chronic liver disease. Acta Cir. Bras. 2013; 28: 502-508.
30. Ohshiro Y, Ma RC, Yasuda Y etal. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. Diabetes 2006; 55: 3112-3120.
31. Adams LA, Feldstein AE. Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev. Gastroenterol. Hepatol. 2010; 4: 623-635.
32. Trenti T, Cristani A, Cioni G, Pentore R, Mussini C, Ventura E. Fructosamine and glycated hemoglobin as indices of glycemic control in patients with liver cirrhosis. Ric. Clin. Lab. 1990; 20: 261-267.